Cite
The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial
MLA
Andrew A Mallick, et al. “The Metformin in Tuberous Sclerosis (MiTS) Study: A Randomised Double-Blind Placebo-Controlled Trial.” EClinicalMedicine, vol. 32, Feb. 2021, p. 100715. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a99a7ac3a6d3cff7968202d9fa12ec46&authtype=sso&custid=ns315887.
APA
Andrew A Mallick, Hannah B Edwards, Marcus Likeman, Mario Cortina-Borja, Sam Amin, Matthew Laugharne, & Finbar O’Callaghan. (2021). The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial. EClinicalMedicine, 32, 100715.
Chicago
Andrew A Mallick, Hannah B Edwards, Marcus Likeman, Mario Cortina-Borja, Sam Amin, Matthew Laugharne, and Finbar O’Callaghan. 2021. “The Metformin in Tuberous Sclerosis (MiTS) Study: A Randomised Double-Blind Placebo-Controlled Trial.” EClinicalMedicine 32 (February): 100715. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a99a7ac3a6d3cff7968202d9fa12ec46&authtype=sso&custid=ns315887.